General Atlantic (GA) has become a significant shareholder in pharmaceutical product development company Rubicon Research by committing up to $100 mn of primary capital and acquiring the stake held by Rubicon’s existing private equity shareholders. All other existing shareholders continue to maintain their shareholding in the company. With this investment from General Atlantic, Rubicon intends to focus on bringing to market innovative medicines to solve fundamental patient needs through the use of its proprietary drug delivery technologies, as well as increase its manufacturing footprint across the world.

(Financial Express)